Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design At ASPC Congress 2024; Topline Data Is Expected First Half Of 2025
Portfolio Pulse from Benzinga Newsdesk
Tourmaline Bio, Inc. (NASDAQ: TRML) presented the design of its Phase 2 TRANQUILITY study at the ASPC Congress 2024. The study evaluates the effects of TOUR006 on hs-CRP levels in CKD patients. Topline data is expected in the first half of 2025, potentially advancing TOUR006 to Phase 3 for ASCVD and other cardiovascular diseases.
August 02, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tourmaline Bio presented the design of its Phase 2 TRANQUILITY study, which evaluates the effects of TOUR006 on hs-CRP levels in CKD patients. Topline data is expected in the first half of 2025, potentially advancing TOUR006 to Phase 3 for ASCVD and other cardiovascular diseases.
The presentation of the Phase 2 TRANQUILITY study design and the expected topline data in the first half of 2025 are significant milestones for Tourmaline Bio. Positive results could advance TOUR006 to Phase 3 trials, which would be a major step forward for the company and could positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100